Free Trial
NYSE:PFE

Pfizer (PFE) Stock Price, News & Analysis

$30.07
+0.80 (+2.73%)
(As of 03:08 PM ET)
Today's Range
$29.44
$30.13
50-Day Range
$27.72
$31.38
52-Week Range
$25.20
$34.12
Volume
17.93 million shs
Average Volume
38.00 million shs
Market Capitalization
$170.39 billion
P/E Ratio
N/A
Dividend Yield
5.59%
Price Target
$34.54

Pfizer MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
14.9% Upside
$34.54 Price Target
Short Interest
Healthy
1.15% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.68
Upright™ Environmental Score
News Sentiment
0.55mentions of Pfizer in the last 14 days
Based on 37 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.14%
From $2.66 to $2.85 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.74 out of 5 stars

Medical Sector

48th out of 927 stocks

Pharmaceutical Preparations Industry

17th out of 425 stocks

PFE stock logo

About Pfizer Stock (NYSE:PFE)

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

PFE Stock Price History

PFE Stock News Headlines

Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains (PFE)
Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.
2 Election-Proof Dividends Growing Up to 67%
How about two bold election predictions—and two payouts that will thrive regardless of the results? My first forecast: Americans will still want to ea
Buy these “two-bagger” stocks
We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.
3 Bargain-Priced Growth Stocks for Fall 2024
3 Bargain-Priced Growth Stocks for Fall 2024
Investors can leverage market volatility to uncover undervalued companies with solid fundamentals and significant growth potential.
weight loss injection with measuring tape Eli Lilly
Eli Lilly’s Path to the Next Trillion Market Capitalization (PFE)
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Ford logo on orange car
These 3 Stocks Pay You More Than 5% to Own Them (PFE)
High dividend yields paired with fundamentally sound and undervalued stocks provide opportunities for both income and long-term capital appreciation.
house frame new construction
Value Investing: Unearthing 3 Hidden Gems in Today's Market (PFE)
Discover undervalued companies and build long-term wealth through the insightful strategy of value investing.
In this photo The logo of Merck and Co, Inc.Merck is an American multinational pharmaceutical company
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why (PFE)
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Buy these “two-bagger” stocks
We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.
syringe and vaccine in hand
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (PFE)
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint
Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/3 Dividend
7/26/2024
Last Earnings
7/30/2024
Dividend Payable
9/03/2024
Today
9/16/2024
Next Earnings (Estimated)
10/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$34.54
High Stock Price Target
$45.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+18.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$55.17 billion
Cash Flow
$2.94 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,666,593,000
Free Float
5,663,193,000
Market Cap
$165.86 billion
Optionable
Optionable
Beta
0.68

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer Inc. has recently received upgraded ratings from multiple analysts, indicating strong confidence in the company's performance and potential growth.
  • Pfizer Inc.'s stock price has been showing positive momentum, trading at a favorable level of $29.01 as of today, which may present a good entry point for investors.
  • The company has a solid track record of consistently beating earnings estimates, as seen in its recent quarterly report where it surpassed expectations by $0.14 per share.
  • Pfizer Inc. has a diverse portfolio of biopharmaceutical products with a global presence, providing stability and potential for revenue growth.
  • With a positive return on equity of 8.42%, Pfizer Inc. demonstrates efficient utilization of shareholder equity to generate profits.

Cons

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Despite recent positive developments, Pfizer Inc. operates in a highly competitive industry with constant regulatory challenges and patent expirations that could impact future revenue streams.
  • The company's dividend payout ratio is currently -2,800.00%, indicating an unsustainable dividend policy that may raise concerns among income-focused investors.
  • Pfizer Inc.'s stock performance has shown volatility in the past, with fluctuations in share price that may pose risks to short-term investors.
  • Market analysts have issued a mix of ratings for Pfizer Inc., with some maintaining a neutral stance, suggesting uncertainty in the company's future performance.
  • The biopharmaceutical sector is subject to rapid technological advancements and changing market dynamics, which could impact Pfizer Inc.'s competitive position and profitability.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 11, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

PFE Stock Analysis - Frequently Asked Questions

How have PFE shares performed this year?

Pfizer's stock was trading at $28.79 at the start of the year. Since then, PFE shares have increased by 4.4% and is now trading at $30.07.
View the best growth stocks for 2024 here
.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, July, 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The business's revenue for the quarter was up 2.1% compared to the same quarter last year.
Read the conference call transcript
.

Does Pfizer have any subsidiaries?

The following companies are subsidiaries of Pfizer: ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and more.

Who are Pfizer's major shareholders?

Pfizer's top institutional investors include Massachusetts Financial Services Co. MA (1.27%), Legal & General Group Plc (0.82%), Bank of New York Mellon Corp (0.74%) and Dimensional Fund Advisors LP (0.59%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb, Alexander R Mackenzie, John D Young and Douglas M Lankler.
View institutional ownership trends
.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV) and Walt Disney (DIS).

This page (NYSE:PFE) was last updated on 9/16/2024 by MarketBeat.com Staff

From Our Partners